Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin Effect on Hepatic and Renal Glucose Metabolism
NCT02981966Phase 4Completed
- Sponsor
- UT Health San Antonio
- Start
- May 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by UT Health San Antonio. Primary endpoint: Endogenous Glucose Production Measurement at 3 weeks. Started May 2019; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02981966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981966.